Job title: Senior Scientist, Biomarker Lead
Within the New Therapeutics Target Discovery team from the R&D department at uniQure, Astrid is leading the early stage biomarker development activities. As a molecular neurobiologist, Astrid has a broad interest in the molecular basis of brain functioning in health and disease. Her previous work in both academic and pharma settings included activities in target discovery, preclinical disease modeling and molecular mechanisms of disease, in relation to neuroendocrinology, neuroimmunology, neuroplasticity and neurodevelopmental disorders. Since joining uniQure at the end of 2016, Astrid has shaped the translational activities of uniQure’s Huntington Disease (HD) gene therapy program, with focus on building the rationale for biomarker panel selection, exploring novel bioanalytical methods, and performing preclinical work in small and large animal models to evaluate biofluid and imaging candidate efficacy measures. With uniQure’s HD program now entering the clinic, she continues to support the clinical team in the core activities related to HD biomarkers for the ongoing phase I/IIa trial.
Panel Discussion: Precision Medicine Beyond Oncology 4:45 pm
What lessons can be learned from oncology to accelerate complex and rare disease drug development? What strategies exist to overcome challenges associated with small population groups? How are diagnostics currently being applied in non-oncology disease indications?Read more
day: Day One
Translatable Biomarkers in Gene Therapy for Huntington Disease: Innovative Approaches & Learnings from Pre-Clinic to the Clinic 4:15 pm
Many challenges are associated to finding adequate efficacy/response biomarkers in neurodegenerative disorders Novel approaches can be tested in adequate models of disease, and in the case of gene therapies, biomarkers may need to be tailored Candidate biomarkers to follow-up efficacy of a gene therapy for Huntington Disease will be addressed, highlighting the experience learnt from…Read more
day: Day One